5392672018-07-012018-09-305392672018-09-305392672018-04-012018-09-305392672018-07-012018-09-30in-bse-fin:OtherExpenses1Member5392672018-07-012018-09-30in-bse-fin:OtherExpenses2Member5392672018-04-012018-09-30in-bse-fin:OtherExpenses1Member5392672018-04-012018-09-30in-bse-fin:OtherExpenses2Memberiso4217:INRiso4217:INRxbrli:shares539267DRHABEEBINE579N01018DR HABEEBULLAH LIFE SCIENCES LIMITEDEquity2018-04-012019-03-312018-11-122018-10-31INRLakhsHalf yearlySingle segmentHEALTH CARE2018-11-1203:00:002018-11-1204:00:002018-07-012018-09-30UnauditedStandalone52920000529200049600000312900009000751400011148000-58560000-58560000000-58560000000-58560000-585600000122137000100.490.40.490.40.980.81. The Unaudited Standalone financial results for the Quarter II and period ended 30, September 2018 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on November 12, 2018. The Statutory Auditors have carried out the Limited Review of the Unaudited Standalone Financial Results in accordance with Regulation 33 of SEBI (LODR) Regulations, 2015). <BR> <BR> 2. The Unaudited standalone financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (lND AS) 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by Securities and Exchange Board of India("SEBI") and Regulation 33 of SEBI (LODR) Regulations, 2015 amd SEBI Circular dated 05th July, 2016. <BR> <BR> 3. Adoption of Ind AS 115 - Revenue from contracts with customers <BR> Effective April 1, 2018, the Company has adopted Ind AS 115 “Revenue from Contracts with Customers” using the cumulative catch-up transition method which is applied to contracts that were not completed as of April 1, 2018. Accordingly, the comparatives have not been retrospectively adjusted. The effect on adoption of Ind AS 115 was insignificant on the financial statements. <BR> <BR> 4. The Company has only one reportable segment as per requirements of AS 108 "Operating Segments" i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required. <BR> <BR> 5. The figures of the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable. <BR> <BR> 6. The results are also available on the webiste of the Company www.drhlsl.com <BR> <BR> 2018-04-012018-09-30UnauditedStandalone8338000083380008070000065660000180001308000020471000-121330000-121330000000-121330000000-121330000-1213300000122137000100.980.810.980.811.961.62Professional charges1443000Other Expenses6071000Professional charges2524000Other Expenses105560003430000015303000487060000487060006435200014800000217680001090005860009674000300220006215900063639000127991000122137000-8830000113307000113307000000063000002344000864400060400001468400014684000127991000